These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 26287854)

  • 21. Lack of evidence for recommended low-density lipoprotein cholesterol treatment targets.
    Modest GA
    Ann Intern Med; 2007 Apr; 146(8):614; author reply 614-5. PubMed ID: 17438326
    [No Abstract]   [Full Text] [Related]  

  • 22. Among statin-treated patients, LDL, non-HDL and apoB cholesterol biomarkers were associated with increased risks of cardiovascular events.
    Sniderman AD; Thanassoulis G
    Evid Based Med; 2013 Apr; 18(2):73-4. PubMed ID: 22893654
    [No Abstract]   [Full Text] [Related]  

  • 23. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
    J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 25. [Significant decline in the rate of cardiovascular incidents].
    Wedekind S
    MMW Fortschr Med; 2015 Jun; 157(11):66. PubMed ID: 26049360
    [No Abstract]   [Full Text] [Related]  

  • 26. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly].
    MMW Fortschr Med; 2005 Aug; 147(33-34):50-1. PubMed ID: 16138640
    [No Abstract]   [Full Text] [Related]  

  • 28. [Inhibitors of PCSK9].
    Petrova-Slater I; Denegri A; Pasotti E; Rossi MG; Spirk D; Riesen WF; Moccetti T; Moccetti M
    Rev Med Suisse; 2017 Apr; 13(558):821-825. PubMed ID: 28727332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors.
    Scherer DJ; Nelson AJ; Psaltis PJ; Nicholls SJ
    Intern Med J; 2017 Aug; 47(8):856-865. PubMed ID: 28401639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Commentary.
    Mooradian AD
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):598; author reply 602. PubMed ID: 16094774
    [No Abstract]   [Full Text] [Related]  

  • 31. [PCSK9 Inhibitors - the magic bullet for LDL cholesterol reduction?].
    Richter K; Barthel A; Bornstein SR; El-Armouche A; Wagner M
    Dtsch Med Wochenschr; 2016 Jun; 141(12):863-9. PubMed ID: 27305302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PCSK9 Inhibitors for Statin Intolerance?
    Waters DD; Hsue PY; Bangalore S
    JAMA; 2016 Apr; 315(15):1571-2. PubMed ID: 27039138
    [No Abstract]   [Full Text] [Related]  

  • 33. Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?
    Aronow WS
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):591-2. PubMed ID: 15972605
    [No Abstract]   [Full Text] [Related]  

  • 34. [Ezetimibe in clinical practice: from laboratory investigations to the IMPROVE-IT trial results].
    Borghi C; Filardi PP
    G Ital Cardiol (Rome); 2015; 16(7-8 Suppl 1):3S-14S. PubMed ID: 26442834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
    Tice JA; Kazi DS; Pearson SD
    JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
    Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG
    Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Commentary.
    Levy DR; Pearson TA
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):597-8; author reply 602. PubMed ID: 16094772
    [No Abstract]   [Full Text] [Related]  

  • 38. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Cholesterol and the aged: ...and the beat goes on.
    Wilson MM
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):600-2; author reply 602. PubMed ID: 15972610
    [No Abstract]   [Full Text] [Related]  

  • 39. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Aim low.
    Nash IS
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):599-600; author reply 602. PubMed ID: 15972609
    [No Abstract]   [Full Text] [Related]  

  • 40. Further LDL Lowering Could Reduce Cardiovascular Risk.
    Mechcatie E; Rosenberg K
    Am J Nurs; 2018 Nov; 118(11):55-56. PubMed ID: 30358599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.